Eosinophil responses during COVID-19 infections and coronavirus vaccination

Lindsley, Andrew; Schwartz, Justin T.; Rothenberg, Marc E.

doi:10.1016/j.jaci.2020.04.021

Cited by 315 publications

(362 citation statements)

References 81 publications

Supporting

Mentioning

323

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Du et al reviewed the medical records of 85 fatal cases of Covid-19 and noted that 81% of the patients had absolute Eos counts below the normal range at the time of admission (26). Notably, Eos levels improved in all patients prior to discharge, suggesting that the resolution of eosinopenia may be an indicator of improving clinical status (27). The pathophysiology of eosinopenia in Covid-19 remains unclear but is likely multifactorial, involving inhibition of Eos egress from the bone marrow, blockade of eosinophilopoesis, reduced expression of chemokine receptors/adhesion factors (28, 29) and/or direct Eos apoptosis induced by type 1 interferons released during acute infection (30).…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Predictability of Blood Parameters on the Course of Covid-19- a retrospective clinical study

Çora

Çelik

2020

Preprint

View full text Add to dashboard Cite

Background In December 2019, clusters of patients with pneumonia of an unkown cause were reported in Wuhan, Hubei Province in China. On january 2020, Chinese scientists identified this as a novel coronavirus, temporarily labelled as, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although recent studies investigating predictors of poor prognosis at an early stage identified exact parameters as a predictor for the disease still controversial. Here we study biochemical and hematologic parameters of 197 patients diagnosed as Covid-19 at our hospital for evaluating the value of these biomarkers for predicting the course of Covid-19 disease.Material and Method197 patients who were diagnosed with Covid-19 at our hospital according to World Health Organisation (WHO) interim guidance were screened between march 2020-may 2020 retrospectiveley for the study. Patients selected from the population of service and intensive care unit (ICU). Biochemical and hematologic parameters retrospectively evaluated for predicting the course of Covid-19 disease.ResultsAmong 197 patient population of service and ICU, hematological and biochemical parameters studied. There was a significiant association found between the parameters neurtophile/lymphocyet ratio, white blood cell, eosynophile, monocyte, lymphocyte counts and high sensitive troponin-I levels and ICU admission. ConclusionWe found increased levels of neutrophile/lymphocyte ratio, white blood cell count and high sensitive troponin-I and decreased levels of eosynophile, monocyte and lymphocyte counts among ICU admitted patients. We concluded that these biochemical and hematologic parameters can be used for the predicting the course of Covid-19 disease.

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Predictability of Blood Parameters on the Course of Covid-19- a retrospective clinical study

Çora

Çelik

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Eosinophils orchestrate the immune response to a respiratory virus, releasing cytotoxic proteins, increasing NO, producing type 1-associated cytokines, mainly IL-12 and IFN-γ, and recruiting CD8 T lymphocytes. 7 Eosinophils clear viral load, thus guarantying recovery from viral infections. As a consequence, it may be hypothesized that allergic To further support the hypothesis that allergy might be "protective," a very recent study provided evidence that allergic sensitization was inversely related to ACE2 expression, and allergen natural exposure and challenge significantly reduced ACE2 expression.…”

Section: Very Few Reports On Pediatric Patients With Covid-19 Have Beenmentioning

confidence: 99%

Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares

Licari

Votto

Brambilla

et al. 2020

Allergy

View full text Add to dashboard Cite

Additional supporting information may be found online in the Supporting Information section. Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flaresTo the Editor, The coronavirus disease 2019 (COVID-19) pandemic is affecting people at any age with a more severe course in patients with chronic diseases or comorbidities, men, and elderly patients. The Centers for Disease Control and Prevention (CDC) initially proposed that patients with chronic lung diseases, including moderate-severe asthma, and allergy may have a higher risk of developing severe COVID-19 than otherwise healthy people ( https://www.cdc.gov/coron aviru s/2019-ncov/speci fic-group s/asthma.html ).Very few reports on pediatric patients with COVID-19 have been presented still now. Dong reported a nationwide case series of 2143 pediatric patients with COVID-19. 1 Children at all ages appeared susceptible to COVID-19, and without gender difference, symptoms were less severe than in adults, even though younger children, mainly infants, were vulnerable to infection. It has been, further, reported that infants and children usually developed mild respiratory symptoms, or they were likely asymptomatic. 2 After that, a study conducted in 140 hospitalized COVID-19 adult patients reported that no patient had asthma or allergy. 3 Another study, concerning 11 COVID-19 patients, reported two children with allergy, but no patient developed distinct symptoms and severe courses. 4 These last

show abstract

“…Eosinophils are mainly found in blood, although they are also found in the gastrointestinal tract and lungs. Lung pathology caused by eosinophils has been observed in RSV and SARS-CoV-1 viral infections [21]. Eosinophils may also contribute to the lung pathology in COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Eosinophil and Anticoagulation in COVID-19 Patients

Arı

Can

Demir

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.Materials and methods: We prospectively evaluated 80 COVID-19 patients, diagnosed using polymerase-chain-reaction test, who were admitted to our clinic and administered LMWH; enoxaparin was applied according to the weight, D-dimer levels, and clinical condition of patients. Anti-Factor Xa levels in blood, drawn 4h after the 3rd dose of LMWH, were measured and a level of <0.2IU/ml was considered subprophylactic. Patients were followed up clinically and anti-Factor Xa levels were re-examined before discharge.Results: Groups 1 and 2 included 13 and 67 patients with subprophylactic (0.18±0.06) and prophylactic (0.43±0.23) anti-Factor Xa levels, respectively. The proportion of eosinophils in patients was significantly higher in group 1 than in group 2 (2.96±2.55 vs 0.90±1.28;p=0.001). At the time of discharge the eosinophilic proportion of patients was significantly higher (3.06±1.49 vs 2.07±1.92;p=0.001) but the activated partial thromboplastin time was significantly lower (22.34±1.38 vs 24.38±3.58; p=0.01) in group 1 than in group 2. Of 14 patients with eosinophil content >4%, 6 were in group 1 ((6/13) 46.2%) while 8 were in group 2 ((8/63) 11.9%); (p=0.009), and all had a D-dimer level <1µg/mL (p=0.03). ROC analysis for the presence of anticoagulation at subprophylactic level revealed an area under curve of 0.79 (95% CI:0.64-0.93); p=0.001).Conclusions: In COVID-19 patients, eosinophil levels could be considered for determining effective prophylactic anticoagulant administration. (NCT04507282)

show abstract

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Cited by 315 publications

References 81 publications

WITHDRAWN: Predictability of Blood Parameters on the Course of Covid-19- a retrospective clinical study

WITHDRAWN: Predictability of Blood Parameters on the Course of Covid-19- a retrospective clinical study

Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares

Eosinophil and Anticoagulation in COVID-19 Patients

Contact Info

Product

Resources

About